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Abstract
Background: Chondroprotective agents (CPA) such as glucosamine, curcumin and diacerein
represent potential remedies for the management of osteoarthritis and several studies have been
performed on their effects in-vitro and in-vivo. For the investigation of chondroprotective action
on chondrocyte gene expression, quantitative real-time RT-PCR is the method of choice.
However, validation of applied normalization strategies represents a crucial and sometimes
neglected step in the analysis process. Therefore, the present study aimed to determine the
expression stability of common reference genes (ACTB, Beta actin; GAPDH, Glyceraldehyde-3-
phosphate; B2M, Beta-2-microglobulin; HPRT1, Hypoxanthine phosphoribosyl-transferase I; SDHA,
Succinate dehydrogenase complex, subunit A; YWHAZ, Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide) under the influence of glucosamine, curcumin
and diacerein in the IL-1β-stimulated C-28/I2 chondrocyte model, using the geNorm software tool.
Results: CPA treatment of C-28/I2 chondrocytes significantly affected the expression level of
many reference genes (p < 0.05). According to their expression stability, geNorm analysis revealed
rankings of the 3 most stable genes (from most stable to least stable) as follows: GAPDH, B2M and
SDHA in glucosamine treated samples and HPRT1, GAPDH and B2M in curcumin or diacerein
treated samples. Interestingly, ACTB was one of the most variably expressed genes throughout all
experiments.
Conclusion: Our study points out the problem of relying on commonly used reference genes
without an accurate validation process. For normalization purposes in gene profiling studies on
glucosamine action, the genes GAPDH, B2M and SDHA are recommended as single reference genes
depending on the expression level of the target gene or more favourably in combination. For
experiments with curcumin and diacerein the use of HPRT1, GAPDH and B2M should be considered.
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Background
Osteoarthritis (OA) is a chronic, degenerative disorder of
unknown cause characterized by gradual loss of articular
cartilage. It is the most common of all joint diseases and
represents a major social and economic burden since its
prevalence increases with age [1]. Currently, classic thera-
peutic approaches are still limited to symptom relieving
drugs or surgical intervention. Chondroprotection with
drugs possessing disease-modifying qualities represents
an alternative concept in the treatment of OA and its clin-
ical potential has been the subject of numerous studies,
both clinical and in-vitro [2-10]. Examples of chondro-
protective agents (CPA) are glucosamine, chondroitin sul-
phate, curcumin, diacerein, rhein, and avocado/soybean
unsaponifiables. However, medical opinion about the
applicability and clinical efficacy of CPA in OA remains
divided. In the case of glucosamine, for example, numer-
ous clinical reports have indicated beneficial effects such
as symptom relief in OA [2,3]. On the other hand, several
reviews have provided criticism of study designs or
processing [11,12]. Moreover, the recently published
'Glucosamine/chondroitin Arthritis Intervention Trial
(GAIT)', which was intended to clarify the effectiveness of
glucosamine and chondroitin in reducing the pain of
osteoarthritis, has generated further controversy by reveal-
ing negative findings and high placebo response [13]. It
should be further noted that to date limited information
regarding synergistic effects, contraindications and drug
interactions of CPA is available [14]. However, the ration-
ale to intervene therapeutically in the course of OA with
pharmacological agents able to improve biosynthetic
processes of chondrocytes accounts for an ongoing inter-
est in the evaluation of CPA. Moreover, these often natu-
ral-sourced agents are widely available, generally well
tolerated and presumably possess more desirable safety
profiles as compared to non-steroidal anti-inflammatory
drugs (NSAIDS). A detailed clarification of the molecular
effects of CPA is therefore regarded as a reasonable and
promising approach leading to progress in understanding
of OA modifying action.
At the molecular level, osteoarthritic tissue destruction
originates from an imbalance of catabolic cytokine and
anabolic growth factor pathways in chondrocytes and syn-
ovial cells. Studies have shown that the sensitive homeos-
tasis of cartilage extracellular matrix is effectively
disturbed by the TNFα/IL-1β driven cytokine cascade [15-
17]. Recent in-vitro studies suggest that CPA have direct
influence on the cytokine cascade resulting in down-regu-
lation of catabolic downstream mediators such as colla-
genase, aggrecanase, NO synthase and prostaglandin E2
[8-10]. For the investigation of chondroprotective action,
IL-1β-stimulated chondrocyte models represent a helpful
tool [7,8,10,18-20]. In these models, chondrocytes cul-
tured in monolayer or alginate beads are incubated with
an inflammatory mediator, such as IL-1β and the CPA of
interest, alone and in combination, and selected targets
are investigated at the protein or gene expression level.
During the analysis of the molecular biological conse-
quences of chondroprotective action, real-time quantita-
tive RT-PCR (qPCR) is the method of choice for
monitoring alterations of gene expression patterns in
chondrocytes [21-25]. qPCR is one of the most powerful
analytical tools for the sensitive and accurate quantifica-
tion of mRNA expression levels in cells of different popu-
lations or under different culture conditions. One of the
main challenges encountered in qPCR data interpretation
is the selection of an appropriate normalization strategy.
Data normalization is required to control for the experi-
mental error introduced during the multistage process of
isolating and processing RNA [26]. Different options
range from standardization of tissue weight or cell num-
bers to the use of artificial molecules incorporated into the
samples [26]. However, the most popular method for
internal control of qPCR data error is the use of reference
genes with presumably stable expression levels under a
variety of experimental conditions. Since several studies
have demonstrated the potential regulation of those refer-
ence genes by the conditions of bioassay [27-31], leading
qPCR investigators have declared that the validation of
reference genes for each experimental situation is a crucial
requirement for the acquisition of biologically meaning-
ful data [26,29,32,33]. In this context, a recent study dem-
onstrated that when a carefully validated reference gene is
used to normalize qPCR data, the results can be signifi-
cantly different from those obtained when an unvalidated
reference gene is used [34]. Nevertheless, a survey of the
recent literature makes it apparent that reference genes are
often used for normalization of qPCR data without any
mention of a validation process. This is also true for
papers on chondrocyte function. Furthermore, only two
studies investigating reference gene stabilities in chondro-
cytes under mechanical loading or between patient sam-
ples, respectively, have been published [35,36].
The present study was designed to obtain a methodologi-
cal evaluation of the influence of chondroprotective
agents on reference gene mRNA levels in the IL-1β stimu-
lated chondrocyte model. We therefore cultured IL-1β-
treated C-28/I2 chondrocytes in the presence of selected
CPA, i.e. glucosamine, curcumin, or diacerein and
assessed the mRNA levels of prominent reference genes by
qPCR. Our results will provide information for future
studies on CPA about appropriate reference genes for
internal standardization of qPCR data in the IL-1β stimu-
lated chondrocyte model.BMC Molecular Biology 2007, 8:13 http://www.biomedcentral.com/1471-2199/8/13
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Results
Optimization and quality assessment of the qPCR protocol
Since the efficiency of reverse transcription reactions
depends on the total amount of RNA, the input RNA for
the reverse transcription step should be identical if various
groups of samples are compared [26]. This requires accu-
rate quantification of the isolated RNA as well as assess-
ment of the RNA integrity. In the present study,
RiboGreen assays of RNA isolated from differently treated
C-28/I2 chondrocytes revealed RNA amounts ranging
from 6.96 μg to 36.3 μg. No correlation between the
amount of total RNA and the different treatments was
found. The integrity of the RNA preparations was verified
by the inspection of the 28S and 18S ribosomal RNA
bands using agarose gel electrophoresis. Efficiency of the
DNase digest was additionally assessed by implementing
minus RT controls for each RNA preparation in the qPCR
experiments. Some of the minus RT control samples
recorded Ct  values of around 32 indicating minor
genomic DNA contamination. However, the ΔCt – sepa-
rating the minus RT controls from the unknown samples
– of more than 13 Ct was regarded as high enough to be
negligible [37]. In summary, all RNA samples were found
suitable for qPCR reactions.
Optimization of primer concentrations is critical for
increasing specificity and sensitivity of the qPCR assay
[33]. The results of the described primer optimization
experiments are presented in Table 1. For all qPCR reac-
tions of the study, these respective primer concentrations
were used. Afterwards, standard curves were prepared to
examine the quality of the overall qPCR assay. Standard
curves of all examined genes revealed high amplification
efficiencies over 4 to 5 orders of magnitude (Table 1) cov-
ering the Ct range of all samples. The R2 values of the
standard curves exceeded 0.996. Gene-specific amplifica-
tion was confirmed by a single peak in the melting-curve
analyses (data not shown). Only ACTB  amplification
resulted in the detection of a second peak, which is known
to originate from the presence of regions with highly dif-
ferent GC content rather than from unspecific reactions
[38]. Moreover, no primer-dimer was detectable in any of
the melting-curves indicating optimal performance of the
primers. The no-template controls (NTC), included in all
qPCR runs, did not record any positive Ct value through-
out the study.
Transcriptional profiling of the reference genes
A real-time qPCR assay, based on SYBR Green detection,
was designed for the transcriptional profiling of six fre-
quently used reference genes (ACTB, GAPDH, B2M,
HPRT1, SDHA, YWHAZ) in the cDNA samples. Figures
1A, B and 1C show the distribution of the Ct values of all
samples under all culture conditions (Table 2) for glu-
cosamine, curcumin and diacerein experiments, respec-
tively. This 'whole error approach' is a simplified way to
visualize the overall error introduced during the whole
assay and gives an overview of the abundance of the genes
in the samples. Since lower Ct values indicate higher num-
bers of starting cDNA molecules, the most abundant ref-
erence genes in C-28/I2 cells were ACTB, GAPDH  and
B2M followed by YWHAZ. The amplification of HPRT1
and SDHA occurred about 5 Ct values later. However, this
'whole error approach' does neither take into account the
influence of qPCR efficiencies, nor does it provide satis-
factory resolution for statistical evaluation of small differ-
ences between study groups. In a further step, the Ct values
of each sample were related to the average Ct value of the
respective untreated control group by the equation E-ΔCt.
Tables 3, 4 and 5 show the relative reference gene expres-
sion levels of IL-1β treated chondrocytes under the influ-
ence of glucosamine, curcumin and diacerein,
Table 1: Function of reference genes, primer sequences, optimal primer concentrations and reaction efficiencies of qPCR 
experiments.
Symbol Function Primer sequence nM Efficiency
ACTB Cytoskeletal structural protein fw: CTGGAACGGTGAAGGTGACA
rv: AAGGGACTTCCTGTAACAATGCA
300
100
1.94 ± 0.01
GAPDH Oxidoreductase in glycolysis and gluconeogenesis fw: GGAGTCCACTGGCGTCTTCAC
rv: GAGGCATTGCTGATGATCTTGAGG
300
600
1.94 ± 0.01
B2M Beta-chain of major histocompatibility complex class I molecules fw: TGCTGTCTCCATGTTTGATGTATCT
rv: TCTCTGCTCCCCACCTCTAAGT
300
900
2.03 ± 0.04
HPRT1 Purine synthesis in salvage pathway fw: TGACACTGGCAAAACAATGCA
rv: GGTCCTTTTCACCAGCAAGCT
300
900
1.94 ± 0.03
SDHA Electron transporter in the TCA cycle and respiratory chain fw: TGGGAACAAGAGGGCATCTG
rv: CCACCACTGCATCAAATTCATG
300
900
2.00 ± 0.01
YWHAZ Signal transduction by binding to phosphorylate serine residues fw: ACTTTTGGTACATTGTGGCTTCAA
rv: CCGCCAGGACAAACCAGTAT
600
600
1.98 ± 0.01
Optimal primer concentrations were determined using a matrix of forward and reverse primers varying in concentration from 50 nM to 900 nM. 
Combinations that gave the lowest Ct value and the highest ΔRn value were selected. qPCR efficiencies for each primer pair were derived from 
standard curves (n = 3) using five-fold dilution series covering a 4 to 5 log dynamic range starting from one randomly selected undiluted cDNA 
sample of the untreated control group.BMC Molecular Biology 2007, 8:13 http://www.biomedcentral.com/1471-2199/8/13
Page 4 of 10
(page number not for citation purposes)
respectively. IL-1β did not provoke significant differences
of any reference gene except for ACTB which was signifi-
cantly up-regulated in the glucosamine (Table 3) and
diacerein (Table 5) experiments (p < 0.05). Regarding the
impact of the CPA used, a trend for dose-dependent
down-regulation of all reference genes was observed for
both the pre-treated and the simultaneously treated study
groups. In contrast, time-dependent down-regulation
seems to occur at the high concentrations of CPA used. We
found that both glucosamine (Table 3) and curcumin
(Table 4) treatment affected the expression level of all ref-
erence genes significantly (p < 0.05). Comparing two sam-
ples, a twofold change in gene expression level is
commonly regarded as the benchmark of biological
meaningfulness [29,35]. Therefore, a less than twofold
change is considered as a requirement for suitability of a
reference gene. In our study, a 48 h incubation of
chondrocytes with high concentrations of glucosamine
(Table 3) and curcumin (Table 4) (5 mM and 50 μM,
respectively) induced most reference genes to exceed this
benchmark of biological meaningfulness. The only excep-
tions were B2M  in the case of glucosamine treatment
(Table 3) and YWHAZ in the case of curcumin treatment
(Table 4). The data further indicate differences in the ref-
erence gene regulation caused by different CPA. For diac-
erein-treated chondrocytes, GAPDH, B2M, HPRT1 and
SDHA were not significantly affected by any culture con-
dition used.
GeNorm analysis
In order to determine the most stable reference genes in
our study, the data were analyzed using the geNorm soft-
ware. Table 6 shows the ranking of the 6 candidate refer-
ence genes according to their expression stability under
the influence of glucosamine, curcumin and diacerein.
The optimal number of reference genes necessary for the
calculation of reliable normalization factors was assessed
calculating the pairwise variations Vn/Vn+1 according to
Vandesompele et al. [32]. RT-PCR normalization factors
were calculated on the basis of the 3 most stable genes and
stepwise inclusion of the other genes in the order of their
expression stability. The pairwise variation Vn/Vn+1 was
calculated between the 2 sequential normalization factors
(NFn and NFn+1). A large variation means that the added
gene has a significant effect on the newly calculated nor-
malization factor and should preferably be included for
calculation. In all 3 experiments, the inclusion of the 4th
reference gene did not contribute significantly to the vari-
ation of the normalization factor (V3/4 value < 0.15).
Based on the proposed cut-off value of 0.15, below which
the inclusion of an additional control gene is not
required, the use of 3 control genes would therefore be
sufficient for normalization in our study. The 3 most sta-
ble reference genes for glucosamine-treated samples were
GAPDH, B2M and SDHA. In contrast, for curcumin and
diacerein-treated samples, HPRT1, GAPDH and B2M pro-
vided the most stable expression levels with SDHA rank-
ing the 6th and 5th positions, respectively. It is remarkable
that ACTB, one of the most prominent and frequently
used reference genes, proved to be one of the most varia-
bly expressed genes under the influence of selected CPA.
Discussion
The claim of real-time qPCR to assess changes of mRNA
expression levels in a quantitative way requires the choice
of an adequate normalization strategy [26]. Normaliza-
tion must be performed to compensate sample-to-sample
and run-to-run variations. Reference genes theoretically
represent a convenient way to normalize qPCR data since
their use controls for all steps of gene expression analysis.
However, the quality of normalized quantitative expres-
sion data cannot be better than the quality of the normal-
izer itself. Any variation in the normalizer will obscure
real changes and produce additional errors. Therefore, the
stability of the reference gene of choice represents the
benchmark for the resolution of the qPCR assay and
directly influences the significance of the results. By geo-
metric averaging of multiple control genes, the geNorm
software tool represents an alternative for accurate nor-
malization of qPCR data, in particular, when the signifi-
cance of subtle gene expression differences is evaluated
[32]. The determination of the most stable reference genes
in a given experimental setup and the subsequent calcula-
tion of normalization factors thus open up the possibility
of reliably studying small expression differences even in
low-copy number genes.
In the present study, we determined the expression stabil-
ity of common reference genes under the influence of glu-
cosamine, curcumin and diacerein in C-28/I2
chondrocytes. Immortalized C-28/I2 cells represent an
alternative to primary human chondrocytes circumvent-
ing certain shortcomings of primary cells such as high
inter-individual variability between different donors and
dedifferentiation during in-vitro culture [39,40]. Moreo-
ver, C-28/I2 cells are known to be reactive to IL-1β [41]
suggesting that they represent a suitable model for inves-
tigating the effects of CPA on the IL-1β-driven catabolic
cascade. The present study design was developed to mirror
experimental protocols that were used in recent studies
[18-25] investigating the activity of CPA in chondrocytes
in the presence of IL-1β. In order to create high variability,
we used 3 different CPA for the treatment of chondrocyte
cultures, i.e. glucosamine, curcumin and diacerein. The
range of concentrations used in the presented experiments
were in accordance with recently published in-vitro stud-
ies [20,23,42]. To mimic different approaches used previ-
ously, the CPA were added to the culture medium either
simultaneously with IL-1β or prior to the addition of IL-
1β.BMC Molecular Biology 2007, 8:13 http://www.biomedcentral.com/1471-2199/8/13
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qPCR cycle threshold values of 6 reference genes among 7 culture conditions (table 2) Figure 1
qPCR cycle threshold values of 6 reference genes among 7 culture conditions (table 2). Distribution of expression 
levels of ACTB, GAPDH, B2M, HPRT1, SDHA, and YWHAZ in IL-1β treated C-28/I2 chondrocytes under the influence of glu-
cosamine (A), curcumin (B) and diacerein (C) is shown as medians (lines), 25th percentile to the 75th percentile (boxes) and 
ranges (whiskers) (n = 63). Samples were normalized to the amount of total RNA.
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The presented data report insignificant impact of IL-1β on
the variability of most reference gene expression levels (p
> 0.05). Only ACTB levels were significantly changed in
the glucosamine and diacerein experiments. In this
regard, the C-28/I2 model is in accordance with results of
Chan et al. [25] who showed that GAPDH was not regu-
lated by IL-1β in primary bovine chondrocytes. Moreover,
our results demonstrated significantly variable expression
levels of all reference genes in C-28/I2 chondrocytes
under most culture conditions containing CPA. It is sug-
gested that this variability was due to both dose and time
dependent effects induced by the CPA. In an attempt to
provide information on the most uniformly expressed ref-
erence genes for studies analyzing chondroprotective
activity, we determined the ranking of 6 candidate genes
according to their expression stability depending on the
CPA under investigation. This ranking was not equivalent
between the 3 different CPA. The high variability of ACTB
in our study further points out the problem of relying on
commonly used reference genes without an accurate vali-
dation process. Therefore, using the geNorm software, we
defined the sets of reference genes suitable for studies on
the presented CPA. GAPDH, B2M and SDHA are proposed
for studies on glucosamine, while HPRT1, GAPDH and
B2M  can be used to investigate curcumin or diacerein
activity. If glucosamine, curcumin and diacerein are to be
compared, the same set as proposed for curcumin or diac-
erein can be used. It is generally recommended that the
gene of interest and the selected reference gene should
roughly be expressed at the same level. Therefore, the
choice of a single reference gene (e.g. GAPDH or SDHA in
glucosamine studies) may be determined by the abun-
dance of the gene of interest. When a study aims at the fine
measurement of small gene expression differences even
the geometric mean of 2 or 3 reference genes could be of
advantage.
Conclusion
In conclusion, our report underlines the importance of
accurate reference gene validation for each qPCR study.
However, this validation process represents an evident
disadvantage of the reference gene normalization strategy,
since remarkable effort and costs are associated with its
realization. In order to provide a reference for future stud-
Table 3: Relative mRNA levels of C-28/I2 chondrocytes under the influence of IL-1β and glucosamine.
Experimental condition mRNA relative to untreated control group (mean ± SD)
ACTB GAPDH B2M HPRT1 SDHA YWHAZ
IL-1β 1.30 ± 0.30 1.05 ± 0.27 1.14 ± 0.22 1.08 ± 0.24 1.00 ± 0.20 0.88 ± 0.16
Simultaneous incubation with glucosamine [c]1 1.27 ± 0.24 1.13 ± 0.18 1.35 ± 0.22 0.93 ± 0.13 0.83 ± 0.14 0.83 ± 0.15
Simultaneous incubation with glucosamine [c]2 0.63 ± 0.16 0.69 ± 0.09 1.04 ± 0.11 0.56 ± 0.06 0.77 ± 0.15 0.61 ± 0.11
Pre-incubation with glucosamine [c]1 0.87 ± 0.11 0.97 ± 0.25 1.11 ± 0.22 0.66 ± 0.16 1.02 ± 0.11 0.74 ± 0.10
Pre-incubation with glucosamine [c]2 0.28 ± 0.05* 0.43 ± 0.07* 0.67 ± 0.15 0.37 ± 0.08* 0.35 ± 0.06* 0.37 ± 0.11*
Glucosamine only 0.60 ± 0.27 0.66 ± 0.22 0.77 ± 0.34 0.15 ± 0.05* 0.20 ± 0.07* 0.37 ± 0.28*
Boldfaced values p < 0.05
*p < 0.05 and change > 2-fold
mRNA levels under the treatment with glucosamine in different experimental conditions are presented relative to the untreated control group 
calculated by the equation E-ΔCt (Mean ± SD, n = 9; value of 1 represents average level of mRNA expression in untreated control group). [c]1, low 
concentration of glucosamine (50 μM); [c]2, high concentration of glucosamine (5 mM).
Table 2: Experimental design
Experimental condition Supplements on days of culture
day 5 day 6
Control - -
IL-1β -I L - 1 β
Simultaneous incubation with CPA [c]1 -[ c ] 1+IL-1β
Simultaneous incubation with CPA [c]2 -[ c ] 2+IL-1β
Pre-incubation with CPA [c]1 [c]1 [c]1+IL-1β
Pre-incubation with CPA [c]2 [c]2 [c]2+IL-1β
CPA only [c]2 [c]2
Supplements added to the chondrocyte culture medium on days 5 and 6 of the culture period are presented. Either glucosamine, curcumin or 
diacerein were used as chondroprotective agent (CPA) in 3 separate experiments. Each experiment followed the presented setup of 7 different 
study groups.
IL-1β, 10 ng/ml recombinant human interleukin-1beta; [c]1, low concentration of glucosamine (50 μM), curcumin (5 μM) or diacerein (5 μM); [c]2, 
high concentration of glucosamine (5 mM), curcumin (50 μM) or diacerein (50 μM).BMC Molecular Biology 2007, 8:13 http://www.biomedcentral.com/1471-2199/8/13
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ies on chondrocyte responses to different agents, we have
defined the sets of suitable reference genes for the molec-
ular biological investigation of glucosamine, curcumin
and diacerein activities. Our findings will facilitate the use
of the reference gene method for the normalization and
data interpretation of CPA effects in the IL-1β stimulated
chondrocyte model, in particular when subtle gene
expression differences are to be investigated.
Methods
Materials
Glucosamine hydrochloride, curcumin, diacerein and
0.25 % Trypsin-EDTA were purchased from Sigma (St.
Louis, MO, USA). Recombinant human IL-1β was
obtained from Strathmann Biotec (Hamburg, D). Primers
for real-time PCR experiments and the mi-Gel Extraction
Kit were from Metabion (Martinsried, D). Dulbecco's
modified Eagle's medium and 100x ITS solution were pur-
chased from Gibco (Lofer, A). The StrataScript First-Strand
Synthesis System and the Brilliant SYBR Green QPCR
Master Mix were from Stratagene (La Jolla, CA, USA). All
other chemicals were of analytical grade and obtained
from Merck (Darmstadt, D) unless otherwise specified.
Cell culture and experimental design
Immortalized C-28/I2 chondrocytes were used for all
experiments in this study. In order to determine the influ-
ence of glucosamine, curcumin and diacerein on reference
gene expression levels in chondrocytes, three sets of indi-
vidual experiments – one for each compound – were per-
formed.
2.3 × 105 chondrocytes were seeded into 25 cm2 culture
flasks (Corning, NY, USA) and cultured for 5 days in
DMEM supplemented with 10 % fetal calf serum (Bio-
chrom AG, Berlin, D), 2 μl/ml gentamycin and 50 μg/ml
ascorbate. On days 5 and 6 the culture medium was
changed to serum-free DMEM supplemented with 1 % (v/
v) 100× ITS (10 μg/ml insulin + 5.5 μg/ml transferrin +
6.7 ng/ml sodium selenite) and 2 μl/ml gentamycin.
Additionally, the particular CPA and/or IL-1β (10 ng/ml)
were added as indicated in Table 2. Thereby, 7 different
conditions for each CPA experiment were created: one
Table 5: Relative mRNA levels of C-28/I2 chondrocytes under the influence of IL-1β and diacerein.
Experimental condition mRNA relative to untreated control group (mean ± SD)
ACTB GAPDH B2M HPRT1 SDHA YWHAZ
IL-1β 1.5 ± 0.63 1.2 ± 0.57 1.10 ± 0.08 1.23 ± 0.46 1.02 ± 0.66 0.89 ± 0.45
Simultaneous incubation with diacerein [c]1 1.03 ± 0.39 1.11 ± 0.40 1.36 ± 0.29 1.26 ± 0.40 1.13 ± 0.34 1.14 ± 0.43
Simultaneous incubation with diacerein [c]2 0.71 ± 0.18 1.02 ± 0.21 1.15 ± 0.20 1.07 ± 0.25 0.88 ± 0.17 0.69 ± 0.17
Pre-incubation with diacerein [c]1 1.21 ± 0.21 1.12 ± 0.33 1.23 ± 0.57 1.29 ± 0.40 1.35 ± 0.39 1.11 ± 0.31
Pre-incubation with diacerein [c]2 0.56 ± 0.07 0.79 ± 0.11 0.96 ± 0.12 1.00 ± 0.13 0.98 ± 0.19 0.7 ± 0.15
Diacerein only 0.43 ± 0.06* 0.63 ± 0.10 0.73 ± 0.09 0.87 ± 0.15 0.88 ± 0.15 0.59 ± 0.07
Boldfaced values p < 0.05
* p < 0.05 and change > 2-fold
mRNA levels under the treatment with diacerein in different experimental conditions are presented relative to the untreated control group 
calculated by the equation E-ΔCt (Mean ± SD, n = 9; value of 1 represents average level of mRNA expression in untreated control group). [c]1, low 
concentration of diacerein (5 μM); [c]2, high concentration of diacerein (50 μM).
Table 4: Relative mRNA levels of C-28/I2 chondrocytes under the influence of IL-1β and curcumin.
Experimental condition mRNA relative to untreated control group (mean ± SD)
ACTB GAPDH B2M HPRT1 SDHA YWHAZ
IL-1β 0.93 ± 0.16 0.86 ± 0.10 1.06 ± 0.17 0.97 ± 0.15 0.91 ± 0.11 0.92 ± 0.13
Simultaneous incubation with curcumin [c]1 0.72 ± 0.07 0.74 ± 0.11 0.85 ± 0.10 0.88 ± 0.11 0.76 ± 0.10 0.78 ± 0.08
Simultaneous incubation with curcumin [c]2 0.41 ± 0.04* 0.89 ± 0.16 0.64 ± 0.06 0.86 ± 0.08 0.61 ± 0.06 0.85 ± 0.11
Pre-incubation with curcumin [c]1 0.87 ± 0.13 0.98 ± 0.15 0.94 ± 0.18 0.97 ± 0.11 0.95 ± 0.23 1.02 ± 0.21
Pre-incubation with curcumin [c]2 0.37 ± 0.06* 0.46 ± 0.05* 0.28 ± 0.04* 0.38 ± 0.04* 0.09 ± 0.02* 0.65 ± 0.06
Curcumin only 0.28 ± 0.01* 0.48 ± 0.06* 0.31 ± 0.03* 0.38 ± 0.05* 0.10 ± 0.01* 0.63 ± 0.04
Boldfaced values p < 0.05
* p < 0.05 and change > 2-fold
mRNA levels under the treatment with curcumin in different experimental conditions are presented relative to the untreated control group 
calculated by the equation E-ΔCt (Mean ± SD, n = 9; value of 1 represents average level of mRNA expression in untreated control group). [c]1, low 
concentration of curcumin (5 μM); [c]2, high concentration of curcumin (50 μM).BMC Molecular Biology 2007, 8:13 http://www.biomedcentral.com/1471-2199/8/13
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control group without additional supplements, one IL-1β
treated group, two groups simultaneously treated with
both IL-1β and CPA at two different concentrations, two
groups pre-incubated with CPA at two different concen-
trations prior to IL-1β addition, and one group treated
with the respective CPA at the higher concentration with-
out the addition of IL-1β. Each of these study groups con-
sisted of three identically treated 'biological' replicates.
Throughout cell culturing, cells were maintained in a
humidified 5 % CO2/95 % air atmosphere at 37°C.
RNA isolation and cDNA synthesis
On day 7 of the culture period, chondrocytes were har-
vested by trypsination using 0.05 % Trypsin-EDTA. The
cells were washed with PBS and total RNA was extracted
immediately using the NucleoSpin RNA II Kit (Macherey-
Nagel, Dueren, D) according to the manufacturer's
instructions. On-column DNase digestion was performed
for all samples during the isolation process. To control for
the integrity of the isolated RNA preparations, all samples
were qualitatively assessed according to standard methods
prior to use. Briefly, a 1.5% denaturing agarose gel was
loaded with 2 μg of total RNA samples and stained with
ethidium bromide after electrophoresis. The quantity of
extracted RNA was determined using the Quant-It
RiboGreen reagent (Molecular Probes, Eugene, USA) and
the quantitative plate-read function of the Stratagene
MxPro QPCR software. An R2 > 0.990 of the standard
curve plots was considered acceptable for accurate RNA
quantification. Reverse transcription (RT) was performed
using the StrataScript First-Strand Synthesis System, fol-
lowing the manufacturer's instructions. Briefly, 2 μg of
total RNA were reverse transcribed in a 20 μl reaction vol-
ume using the manufacturer-supplied oligo(dT) primers.
Minus RT controls were prepared for each sample using
the identical procedure except for the omission of reverse
transcriptase. All cDNA preparations and minus RT con-
trols were diluted at a ratio of 1:10 with RNase free water
prior to real-time PCR.
Reference gene selection and primer optimization
Six reference genes (ACTB, GAPDH, B2M, HPRT1, SDHA,
YWHAZ) belonging to different functional classes were
selected to reduce the chance that these genes might be co-
regulated (Table 1). Primers for GAPDH were designed
using AlleleID 2.01 software (Premier Biosoft, CA, USA)
and the Genbank sequence NM_002046. In order to
avoid non-specific product formation, the primers were
designed across exon junctions and with minimized self
and cross dimer ΔG values. Additionally, BLAST analyses
were performed to verify specificity. Primer sequences for
all other reference genes were used as described by Vande-
sompele et al. [32]. Amplicon sizes were 140 bp for ACTB,
165 bp for GAPDH, 86 bp for B2M, 94 bp for HPRT1, 86
bp for SDHA and 94 bp for YWHAZ. Gene specific prim-
ers were used to amplify respective PCR products in order
to provide sufficient template material for primer concen-
tration optimization. PCR amplifications were performed
using GoTaq DNA Polymerase (Promega, Wisconsin,
USA) in a 50 μl reaction volume (10 μl of 5x Colourless
Go Taq Reaction Buffer, 1 μl of PCR Nucleotide Mix, 5 μl
of gene specific forward and reverse primer, 0.25 μl of
GoTaq DNA polymerase, 2 μl of template DNA, and
nuclease-free water to 50 μl). The PCR program consisted
of an initial denaturation step at 95°C for 2 min, followed
by 35 cycles at 95°C for 45 s, at 55°C for 45 s and at 72°C
for 1 min, and a final extension step at 72°C for 5 min.
Amplified PCR products were diluted with bromophenol
blue solution at a ratio of 1:4 and purified by gel electro-
phoresis using a 1% agarose gel. After staining with ethid-
ium bromide, the designated bands were cut out of the
agarose gel and the products were extracted from the gel
using the mi-Gel Extraction Kit according to the manufac-
turer's instructions. Optimization of primer concentra-
tions for the qPCR experiments was performed by qPCR
assays as described below using different primer concen-
trations and a 1:103 dilution of purified PCR products as
templates. Optimal primer pairs for each reference gene
were identified selecting the combination that gave the
lowest Ct value and the highest ΔRn value.
Real-time qPCR
All qPCR reactions were performed in 25 μl reaction mix-
tures containing 1 μl cDNA, 12.5 μl Brilliant SYBR Green
QPCR Master Mix, primer pairs as listed in Table 1, and
nuclease-free water to 25 μl. Each biological replicate was
Table 6: Ranking of the reference genes as determined using the geNorm software tool.
Glucosamine Curcumin Diacerein
GAPDH/B2M HPRT1/GAPDH HPRT1/GAPDH
SDHA B2M B2M
HPRT1 ACTB YWHAZ
ACTB YWHAZ SDHA
YWHAZ SDHA ACTB
The genes are ranked in order of their expression stability under the influence of glucosamine, curcumin and diacerein decreasing from top to 
bottom. The 2 most stable reference genes in each experiment cannot be ranked in order due to the required use of ratios for the calculation of 
gene expression stability. The reference genes proposed for comparing the 3 chondroprotective agents are displayed in bold letters.BMC Molecular Biology 2007, 8:13 http://www.biomedcentral.com/1471-2199/8/13
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run in triplicate on a Mx3000P QPCR system (Stratagene).
Thermocycling conditions consisted of an initial polymer-
ase activation step at 95°C for 10 min, followed by 35
cycles at 95°C for 30 s, at 55°C for 1 min, and at 72°C for
1 min. Afterwards, melting curves were generated to con-
firm a single gene-specific peak and to detect primer-
dimer formation by heating the samples stepwise from
55°C to 95°C while continuously monitoring the fluores-
cence. NTC were included in each run to control for con-
taminations. Minus RT controls were run to verify the
efficiency of the on-column DNase digestion. The results
were analyzed using the MxPro real-time QPCR software
(Stratagene). Baselines and thresholds were automatically
set by the software and used after manual inspection. The
crossing point of the amplification curve with the thresh-
old represented the cycle threshold (Ct). PCR efficiencies
for each primer pair were derived from standard curves
using five-fold dilution series covering a 4 to 5 log
dynamic range starting from one randomly selected undi-
luted cDNA sample of the untreated control group. The
reactions were run in duplicate and no-template controls
were included.
Data presentation and calculations
Results were exported to Microsoft Excel and GraphPad
Prism for further analyses. For each test compound, the
distribution of the expression levels (Ct values) for each
reference gene under the 7 experimental conditions was
displayed as Box and Whiskers plots. In a next step, data
within each experiment were normalized to the average
level of mRNA expression (Ct value) of the respective con-
trol group using the relationship E-ΔCt (E, efficiency; ΔCt,
difference between Ct values). Statistics were performed
using one-way ANOVA with post-hoc Dunnett tests com-
paring each study group with the untreated control group
(significance p < 0.05). The geNorm application software
for Microsoft Excel was additionally used as described by
Vandesompele et al. [32] to identify the most stable refer-
ence gene under the described conditions, and to deter-
mine the optimal number of reference genes required for
reliable normalization of qPCR data.
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